Article
Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
The Journal of antimicrobial chemotherapy - 1 Dec 2020
Ndashimye Emmanuel, Avino Mariano, Olabode Abayomi S, Poon Art F Y, Gibson Richard M, Li Yue, Meadows Adam, Tan Christine, Reyes Paul S, Kityo Cissy M, Kyeyune Fred, Nankya Immaculate, Quiñones-Mateu Miguel E, Arts Eric J
Abstract excerpt
BACKGROUND: Increasing first-line treatment failures in low- and middle-income countries (LMICs) have led to increased use of integrase strand transfer inhibitors (INSTIs) such as dolutegravir. However, HIV-1 susceptibility to INSTIs in LMICs, especially with previous raltegravir exposure, is poorly understood due to infrequent reporting of INSTI failures and testing for INSTI drug resistance mutations (DRMs)....
Topics
Join the communities discussing this publication.